PIK3CA and head and neck squamous cell carcinoma: Our present results indicated that hot spot activating PIK3CA and RAS mutations were biomarkers of cetuximab resistance among HNSCC patients in the first-line recurrence setting, as is also the case in colorectal cancer14,15.